Back to search

Article

The Changes in BRCA Mutation Status and Their Impact on Recurrence in Ovarian Cancer Patients After Oral PARPi Treatment

2025-07-14

Abstract excerpt

<title>Abstract</title> <p>Background The present study was designed to investigate the genetic mutations in patients with recurrent ovarian cancer (OC), with a particular focus on comparing the genetic profiles prior to and following relapse in individuals who had previously been treated with Olaparib. Methods This retrospective study enrolled nine patients with OC between November 2017 and October 2023. Eligibl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
08fec185-cb00-576f-897e-a42f6df579d3
DOI
10.21203/rs.3.rs-6859028/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Changes in BRCA Mutation Status and Their Impact on Recurrence in Ovarian Cancer Patients After Oral PARPi TreatmentDOI 10.21203/rs.3.rs-6859028/v1
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studySemantic proximity
Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.Semantic proximity
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.Semantic proximity
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific driversSemantic proximity
Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian CancerSemantic proximity
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers.Semantic proximity
The clinical pathological characteristics and prognostic Relevance of Homologous Recombination Repair Gene Mutations in Ovarian Cancer Patients：A Retrospective Cohort StudySemantic proximity
Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA -Mutated Ovarian CancerSemantic proximity
Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.Semantic proximity
Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.Semantic proximity
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.Semantic proximity
PARPis after PARPis in patients with recurrent epithelial ovarian cancer: A single institutional experienceSemantic proximity
Select a neighboring publication to make it the new centre.